- Premier syndicate comes together to fund Phase 2/3 development of NDX-1017 for treatment of Alzheimer's disease SEATTLE, June 4, 2020-- Athira Pharma, Inc., a clinical-stage company developing innovative first-in-class regenerative therapies with the potential to restore brain function, today announced the closing of an $85 million Series B financing.